Biodegradable Ionizable Lipids for Low-Toxicity Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug delivery systems, particularly viral systems, face challenges such as immunogenicity, size limitations, and tissue accumulation, leading to inflammation and hepatotoxicity, while lipid-DNA conjugates suffer from inflammation and non-specific tissue distribution.
Innovation Solution
Development of ionizable lipids with biodegradable ester bonds, formulated into nanoparticles with specific ratios of phospholipids and PEG-lipids, to enhance drug encapsulation and targeting, reducing side effects and improving tissue specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral delivery systems are used for gene therapy, then delivery effectiveness is improved, but immunogenicity and tissue accumulation occur causing inflammation and hepatotoxicity
Solution Approach 1:
The patent extracts and eliminates the harmful components (viral capsids and immunogenic elements) while retaining the effective gene delivery function. By using synthetic lipid nanoparticles instead of viral vectors, the system removes the source of immunogenicity and tissue accumulation problems while maintaining nucleic acid delivery capability
Solution Approach 2:
The patent employs composite lipid formulations containing multiple components (ionizable lipids, phospholipids, cholesterol, and PEG-lipids) to create nanoparticle systems that combine effective gene delivery with reduced toxicity. The composite structure allows optimization of both delivery performance and biocompatibility
2Reliability
If lipid-DNA conjugates are used for drug delivery, then cellular-level delivery capability is improved, but inflammation and non-specific tissue distribution occur in vivo
Solution Approach 1:
The patent applies local quality by designing ionizable lipids with specific pKa values that enable pH-responsive charge transitions. The lipids remain neutral at physiological pH to reduce inflammation and non-specific binding, but become positively charged in the acidic endosomal environment to facilitate nucleic acid release and cellular delivery
Solution Approach 2:
The patent utilizes parameter changes in the ionizable lipid structure, specifically the pKa value, to control the charge state and delivery mechanism. The pH-dependent ionization allows the system to transition from a stealth configuration (neutral at pH 7.4) to an active delivery configuration (positive charge in acidic endosomes), resolving the contradiction between reducing inflammation and maintaining delivery effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ionizable lipids effectively deliver anionic drugs, including nucleic acids, with high encapsulation efficiency and minimal hepatotoxicity, demonstrating superior gene expression and cellular uptake.
Implementation Method 1
ionizable lipid containing a biodegradable ester bond
Data Source
AI summary
The present disclosure relates to a novel ionizable lipid containing a biodegradable ester bond. The ionizable lipid containing an ester bond, according to the present disclosure, stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, in delivering nucleic acids, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.